Two additional pharmacogenomic-directed trials in patients with NSCL cancer are evaluating the predictive value of ERCC1 status in relation to adjuvant cisplatin-gemcitabine (SWOG) or erlotinib with or without cisplatin (IFCT) therapy. This evidence concerns the gene ERCC1 and cancer.